When a cancer recurrence goes unmonitored: does the failure to follow up give rise to a medical negligence claim in NSW?

That account — or something close to it — is one of the most consistent patterns in the medical negligence cases that reach courts and complaints bodies in Australia. Treatment ends. Surveillance does not begin. The patient, relieved and exhausted, assumes that silence means safety. It does not. What follows is an examination of what the standard of care actually requires when a serious illness has been treated, and what the law says when that standard is not met.

What recurrence monitoring is and why it exists

After a patient completes treatment for a serious illness — most commonly cancer, but also conditions including cardiac disease, autoimmune disorders, and certain neurological conditions — the clinical relationship does not end. It changes. The treating team’s obligation shifts from active treatment to structured surveillance: a planned programme of reviews, investigations, and clinical assessments designed to detect any return of the disease at the earliest possible point.

Recurrence monitoring exists because early detection of a returning illness almost always produces better outcomes than late detection. For many cancers, the difference between detecting a recurrence at a localised stage versus a metastatic stage is the difference between curative treatment and palliative care. That is not a contested clinical proposition. It is the foundation on which every major oncology guideline in Australia is built.

According to the Australian Institute of Health and Welfare, cancer is the leading cause of disease burden in Australia, with approximately 165,000 new cases diagnosed in 2023.¹ Survival rates have improved substantially over the past two decades — but that improvement depends in part on structured post-treatment surveillance catching recurrences before they become unmanageable. The monitoring programme is not a courtesy. It is a clinical obligation.

For more background on specific conditions and their management, Healthdirect Australia provides condition-specific information written for patients.

What the standard of care requires — and when it is breached

The “standard of care” is a legal concept — it means the standard of conduct that a reasonably competent clinician in the same specialty, with the same information, would have met in the same circumstances. It is an objective test. What this particular clinician intended, believed, or was under pressure to achieve is not the measure. The measure is what a competent peer would have done.

For recurrence monitoring, the standard of care has several distinct components. Each one represents a point at which a failure can occur — and each failure carries its own legal significance.

The discharge planning obligation

At the point of completing active treatment, the treating clinician — whether an oncologist, surgeon, haematologist, or specialist physician — carries an obligation to establish a structured follow-up plan. That plan must specify the frequency of reviews, the investigations required at each review, and the clinical signs or results that would trigger escalation. A plan that exists only in the clinician’s head, and is never communicated to the patient or documented in the records, does not satisfy this obligation.

The surveillance execution obligation

Establishing a plan is not enough. The plan must be executed. That means someone — a named clinician or clinical team — must take responsibility for ensuring that each scheduled review occurs, that the required investigations are ordered and completed, and that results are reviewed by a clinician with the expertise to interpret them correctly.

This is where the monitoring system most commonly breaks down. A plan exists on paper. The patient is discharged to their GP. The GP receives a letter that mentions follow-up but does not specify who is responsible for ordering the surveillance CT at twelve months. Nobody orders it. The patient, who was told they were “doing well,” does not know to ask. Eighteen months later, the recurrence is found — at a stage where it was no longer treatable with curative intent.

The abnormal result obligation

When a surveillance investigation returns an abnormal result — a rising tumour marker, a new lesion on imaging, an unexpected finding on examination — the clinician who receives that result carries an immediate obligation to act. That action must be timely, must involve appropriate specialist input, and must be documented. A result that sits in a system unreviewed, or that is reviewed but not acted upon, represents a distinct and serious failure.

Where care breaks down — specific failure patterns

Failures in recurrence monitoring do not usually happen because a clinician made a single dramatic error. They happen because a system — built on assumptions about who is responsible, who will follow up, and who will notice when something is missed — quietly fails. Understanding the specific failure patterns matters, because each one maps to a different legal question.

No surveillance plan at discharge

The treating specialist completes the final cycle of treatment, declares the patient in remission or disease-free, and discharges them to their GP with a letter that summarises what was done. The letter does not specify a surveillance schedule. It does not name who is responsible for ordering the next scan. It does not tell the patient what symptoms should prompt them to return urgently.

The GP receives the letter, files it, and waits for the patient to present with a problem. The patient, who has been through an exhausting treatment process and has been told the good news, does not know that the absence of a scheduled appointment is itself a clinical failure. Two years pass. She presents with back pain. The imaging shows metastatic disease in her spine.

This failure pattern is structural. It happens because the handover between specialist and GP is treated as an administrative event rather than a clinical one. The mechanism is a combination of system design failure and an assumption — rarely examined — that the GP will take responsibility for surveillance the specialist never formally delegated.

Abnormal result not acted upon

A surveillance investigation is ordered and completed. The result is abnormal — a tumour marker has risen, or imaging shows a new lesion that was not present at the previous scan. The result arrives in the clinical system. Nobody reviews it within a clinically appropriate timeframe. Or it is reviewed, but the clinician who reviews it does not recognise its significance, and no action follows.

He had his six-month blood test. The result came back elevated. The GP’s practice received it, but the GP who ordered it was on leave. The result sat in the system for three weeks before anyone looked at it. By the time a referral was made, the window for surgical intervention had closed.

This failure is cognitive and systemic. Cognitive, because interpreting a rising tumour marker in the context of a patient’s cancer history requires specialist knowledge that a generalist GP may not have. Systemic, because most GP practices do not have a robust process for ensuring that abnormal results are reviewed by a clinician with the expertise to act on them correctly.

Patient discharged from specialist care without a transition plan

After a defined period of specialist follow-up — often two or three years — the patient is formally discharged from the oncologist’s or surgeon’s care. This discharge is clinically appropriate if the patient’s risk of recurrence has genuinely diminished to a level that primary care surveillance can manage. It is not appropriate if the patient is discharged without a clear written plan specifying what the GP must monitor, at what intervals, and under what circumstances the patient must be referred back to specialist care.

The distinction matters legally. A specialist who discharges a patient to primary care without a documented transition plan, and where that patient subsequently develops a recurrence that primary care fails to detect, may share responsibility for the harm — even if the specialist’s own direct care was otherwise competent.

Symptoms reported and dismissed

The patient presents to their GP with symptoms that, in the context of their cancer history, should prompt urgent investigation. Fatigue, unexplained weight loss, localised pain, or a new lump. The GP attributes the symptoms to something benign — stress, ageing, a musculoskeletal complaint — and does not order investigations or refer back to the specialist.

She told her GP three times over six months that something felt wrong. Each time, she was reassured. On the fourth visit, she insisted on a scan. The scan showed a recurrence that had been growing, undetected, for at least eight months.

This failure is one of cognitive bias — specifically, the tendency to interpret new symptoms in a patient with a cancer history through a lens of reassurance rather than vigilance. The standard of care for a GP managing a patient with a prior cancer diagnosis requires a lower threshold for investigation than would apply to a patient without that history. Failing to apply that lower threshold is a breach.

The Australian Commission on Safety and Quality in Health Care has identified failures in clinical handover and follow-up as a persistent patient safety risk across the Australian health system, noting that the transition between specialist and primary care is a particularly high-risk point for information loss and accountability gaps.

The legal framework in NSW

Medical negligence claims in NSW are governed primarily by the Civil Liability Act 2002 (NSW). That Act sets out the legal tests for breach and causation, and it creates a specific defence — the peer professional opinion defence — that clinicians frequently rely upon. Understanding how that defence works, and where it does not apply, is essential to understanding whether a failure in recurrence monitoring can ground a claim.

The peer professional opinion defence — section 5O

Section 5O of the Civil Liability Act 2002 (NSW) provides that a clinician does not breach their duty of care if they acted in a manner that was widely accepted by peer professional opinion as competent professional practice. In plain terms: if a body of competent clinicians would have done the same thing, the defendant clinician is not liable — even if another body of competent clinicians would have done something different.

This defence has real force. But it has limits. Section 5O(2) provides that the defence does not apply if the court considers the peer professional opinion to be irrational. And critically, the defence requires that the opinion be “widely accepted” — not merely held by one or two experts retained for litigation. A clinician who discharged a patient without any surveillance plan, in circumstances where every relevant clinical guideline required one, cannot shelter behind section 5O. No rational body of peer opinion supports the complete absence of a monitoring plan for a patient at known risk of recurrence.

Causation — section 5D

Section 5D of the Civil Liability Act 2002 (NSW) governs causation — the requirement that the breach caused the harm. The primary test is the “but for” test: but for the clinician’s failure, would the harm have occurred? In recurrence monitoring cases, this question is answered by expert oncological evidence about what the outcome would have been if the recurrence had been detected at the earlier point when monitoring should have caught it.

Causation in these cases is often the most contested element. The defendant will argue that even with timely detection, the outcome would have been the same. The plaintiff will lead expert evidence that earlier detection would have permitted curative treatment, or would have significantly extended life expectancy, or would have avoided the need for more aggressive treatment. Courts assess this evidence carefully, and the outcome turns on the quality of the expert opinion on both sides.

What the law requires here is that the plaintiff establish, on the balance of probabilities, that the breach materially contributed to the harm. That is a lower bar than certainty — but it still requires credible expert evidence about what earlier detection would have changed.

Who holds the duty of care

In recurrence monitoring cases, the duty of care may rest with multiple clinicians simultaneously. The treating oncologist or surgeon holds a duty at the point of discharge. The GP holds a duty once the patient is under their care. A specialist who receives a referral and fails to act on it holds a duty from the moment of that referral. A hospital or health service that operates the clinical system through which results flow holds a duty to ensure that system functions safely.

The question of which clinician breached their duty — and whether that breach caused the harm — is often the central dispute in these cases. In my view, the most important analytical step is to map the specific clinical decisions that were made (or not made) against the specific obligations that applied at each point. That mapping is what the medical records, the clinical guidelines, and the expert evidence must support.

For a detailed explanation of how medical negligence claims work in NSW, including the procedural steps and evidentiary requirements, see Reframe Legal — Medical Negligence.

When a failure to monitor may amount to medical negligence

Not every gap in follow-up is negligence. A patient who declines surveillance appointments, or who moves interstate without notifying their treating team, or whose recurrence occurs in a form that no surveillance programme would have detected, does not automatically have a negligence claim. The law requires a breach of the standard of care that caused harm. What follows are the specific factual patterns that, in my analysis, engage that legal threshold.

No survivorship care plan was documented at discharge

If the treating specialist discharged the patient after completing active treatment without documenting a survivorship care plan — specifying surveillance intervals, required investigations, and escalation criteria — that failure engages the breach element directly. Cancer Australia’s national guidance, the relevant specialty body guidelines, and the Australian Commission on Safety and Quality in Health Care’s standards all require a documented plan. A clinician who does not produce one has departed from the standard without any rational peer professional opinion to support that departure.

The causation question then turns on whether, had a plan been in place and followed, the recurrence would have been detected at an earlier and more treatable stage. Expert oncological evidence will address that question by reference to the tumour type, the growth rate, and the surveillance modalities that the plan should have specified.

A scheduled surveillance investigation was not ordered

A plan existed. The twelve-month CT scan was specified in the plan. Nobody ordered it. The patient was not recalled. The scan that should have been done at twelve months was not done until twenty-two months later — when the patient presented with symptoms. By that point, the recurrence had spread beyond the reach of curative treatment.

This scenario engages both breach and causation clearly. The breach is the failure to execute the plan. Causation is established by expert evidence that the recurrence, had it been detected at twelve months, would have been at a stage amenable to curative treatment. The defendant will need to show either that the plan did not require the scan, or that the scan would not have detected the recurrence at twelve months, or that detection at twelve months would not have changed the outcome. Each of those arguments requires expert support — and each is contestable.

An abnormal result was not acted upon within a clinically appropriate timeframe

A surveillance blood test returned an elevated tumour marker. The result was received by the practice. No clinician reviewed it within a clinically appropriate timeframe. No referral was made. When the patient presented six weeks later with symptoms, the recurrence was already at an advanced stage.

The breach here is the failure to review and act on the result. The causation question is whether, had the result been acted upon promptly — within days, not weeks — the recurrence would have been detected at an earlier stage and treated more effectively. For many tumour types, a six-week delay in acting on a rising tumour marker is clinically significant. Expert evidence will quantify that significance.

Symptoms consistent with recurrence were dismissed without investigation

The patient presented to their GP with symptoms that, in the context of their cancer history, required investigation. The GP did not order investigations and did not refer back to the specialist. The patient presented again with the same or worsening symptoms. Again, no investigation was ordered. By the time imaging was finally performed, the recurrence had progressed to a stage that significantly worsened the prognosis.

This scenario engages the GP’s duty of care directly. A GP managing a patient with a prior cancer diagnosis must apply a lower threshold for investigation than would apply to a patient without that history. The standard is not perfection — it is what a competent GP, with knowledge of the patient’s cancer history, would have done when presented with those symptoms. If a competent GP would have ordered imaging or referred back to the specialist, and this GP did not, the breach is established.

The long-term consequences when monitoring fails

When a recurrence goes undetected because monitoring was not conducted, the harm is not simply the recurrence itself. The harm is the stage at which the recurrence is eventually found — and everything that flows from that stage.

Physical consequences

A recurrence detected early — at a localised stage — is often treatable with curative intent. Surgery, targeted radiation, or a second course of systemic therapy may eliminate the disease entirely. A recurrence detected late — after it has spread to regional lymph nodes, adjacent organs, or distant sites — is frequently not curable. Treatment at that stage is palliative: it may extend life and manage symptoms, but it does not eliminate the disease.

The physical consequences of late-stage detection include the need for more aggressive treatment — more extensive surgery, higher-dose chemotherapy, broader radiation fields — with correspondingly greater side effects and recovery burdens. For some patients, late detection means the loss of an organ or limb that could have been preserved with earlier intervention. For others, it means the transition from curative to palliative care — a shift that carries its own profound physical and psychological weight.

Psychological consequences

The psychological impact of discovering that a recurrence was growing undetected — and that monitoring should have caught it — is distinct from the psychological impact of the recurrence itself. Patients in this situation frequently describe a specific form of distress: the knowledge that the system that was supposed to protect them failed, and that the harm they are now living with was, at least in part, avoidable.

According to research published in the Medical Journal of Australia, rates of anxiety and depression among cancer survivors are significantly elevated compared to the general population, and the experience of a recurrence — particularly one perceived as preventable — is associated with higher rates of post-traumatic stress symptoms.³ That psychological harm is a recognised head of damage in a negligence claim.

Financial consequences

Late-stage cancer treatment is expensive. More aggressive chemotherapy regimens, extended hospital admissions, palliative care services, home modification, and unpaid carer burden all represent real financial costs. Lost income — from the patient’s inability to work during treatment and recovery, or permanently — compounds those costs significantly.

For a patient who was working full-time at the time of their original diagnosis and who expected to return to work after treatment, a late-detected recurrence that results in permanent incapacity represents a substantial economic loss. That loss is quantifiable, and it forms a significant component of the damages in a successful negligence claim.

What compensation covers in NSW

A successful medical negligence claim in NSW can recover compensation across several categories of loss. The Civil Liability Act 2002 (NSW) governs both the categories of recoverable loss and the thresholds that apply to non-economic loss claims.

General damages compensate for pain, suffering, and loss of enjoyment of life. Under section 16 of the Civil Liability Act 2002 (NSW), non-economic loss is only recoverable if the severity of the harm is assessed at 15% or more of the most extreme case. In plain terms: minor or temporary harm does not cross the threshold. Serious, permanent, or life-altering harm almost always does. For a patient whose recurrence was detected late because monitoring was not conducted, and who has suffered permanent physical harm or a significantly shortened life expectancy as a result, the threshold is generally met.

Special damages cover past and future medical expenses, lost income (past and future), the cost of care provided by family members, and the cost of home modification or assistive equipment. In cases involving late-detected recurrence, these figures can be substantial — particularly where the patient was working at the time of the original diagnosis and has lost the capacity to return to work.

These figures are general reference ranges only. Each case turns on its own evidence — medical records, expert clinical opinion, and economic reports that quantify the actual loss.

The limitation period for medical negligence claims in NSW is three years under the Limitation Act 1969 (NSW). For cases involving a failure to monitor recurrence, the limitation period may run from the date the patient discovered — or ought reasonably to have discovered — that the harm was caused by a failure in care. That is not necessarily the date of the original treatment. It may be the date the late-stage recurrence was diagnosed, or the date the patient first received advice that the monitoring failure contributed to the outcome. This is a complex area of law, and the specific facts of each case determine when the clock starts running.

How to think about your own situation

The questions below are not a legal test. They are prompts designed to help you think clearly about whether your experience — or the experience of someone you care for — may warrant a closer examination of the clinical record.

These questions are not a legal test. But the pattern they reveal — when several of them point in the same direction — is often the starting point for a proper examination of whether the standard of care was met. The medical records will show what was ordered, what was received, what was reviewed, and what was done. That documentary record is the foundation of any legal analysis.

For a detailed explanation of the process involved in examining a potential claim, see Reframe Legal — How Medical Negligence Claims Work in NSW.

Why uncertainty about what happened is normal — and what to do with it

Most people in this situation feel uncertain. They are not sure whether what happened to them was a genuine failure or simply an unfortunate outcome. They wonder whether they are being unreasonable, or whether they are misremembering the sequence of events. Many have been told — by clinicians, by family members, or by their own internal voice — that these things happen, that cancer is unpredictable, and that nobody is to blame.

That uncertainty is a rational response to a genuinely confusing experience. It does not mean nothing went wrong. The law does not require a patient to be certain that negligence occurred before they can have their records examined. Legal analysis works from objective evidence — the medical records, the clinical guidelines that applied at the time, and the expert opinion of clinicians who can assess whether the care provided met the standard.

The standard of care is an objective test. What matters is not what this particular clinician intended, or what they believed they were doing, or what pressures they were under. What matters is what a competent clinician in the same specialty, with the same information, would have done. That question is answered by examining the records and applying the guidelines — not by asking whether the clinician was a good person or had good intentions.

In my view, the most important thing to understand is this: the question of whether the standard of care was met is a factual and legal question, not a moral one. Examining it does not require you to believe that your clinician was malicious or incompetent. It requires only that you be willing to have the facts examined honestly.

For information about informed consent obligations — which are a separate but related area of clinical duty — see Reframe Legal — Informed Consent and Medical Negligence. Where a patient was not told about the importance of post-treatment surveillance, or was not told what symptoms should prompt urgent re-presentation, that failure may engage consent obligations as well as monitoring obligations.

Clinicians in Australia are registered with AHPRA — Australian Health Practitioner Regulation Agency, which maintains registration standards and handles complaints about registered health practitioners. A complaint to AHPRA is a separate process from a civil negligence claim, and the two processes serve different purposes — but both may be relevant depending on the circumstances.

Dr Rosemary Listing is a lawyer with a PhD in law, specialising in medical negligence. Her legal practice concentrates on cases where clinical care in NSW failed to meet the standard the law and the profession require. Her doctoral research and legal practice have given her a rigorous command of the clinical standards against which negligent conduct is measured, and of the evidentiary requirements those claims must satisfy in NSW courts.

Cases involving failures in recurrence monitoring sit at a particularly demanding intersection of clinical and legal complexity. The clinical question — whether monitoring was conducted as the applicable guidelines required — must be answered by reference to the specific tumour type, the surveillance modalities available, and the intervals that the relevant specialty body mandated at the time. The legal question — whether that failure caused the harm — requires expert oncological evidence about what earlier detection would have changed. Neither question is straightforward, and the interaction between them is where these cases are won or lost.

The cases that have reached NSW courts, and the complaints recorded by the Health Care Complaints Commission, reveal a consistent pattern in how recurrence monitoring failures occur and how they are assessed. The failure is almost never a single dramatic event. It is a sequence of small omissions — a plan not documented, a result not reviewed, a symptom not investigated — that accumulates into a harm that was, at each individual step, preventable. Courts and complaints bodies have consistently found that each step in that sequence carries its own legal significance.

The people who seek a legal examination of their records in these cases are not looking to blame anyone. They want to understand what happened and whether it could have been different. Many waited a long time before seeking any kind of examination of the facts — often because they doubted themselves, or because those around them discouraged them from asking questions, or because they were still in the middle of treatment and did not have the capacity to think about anything else.

Dr Listing examines medical records alongside expert clinical opinion and applies the legal standard — not to assign blame, but to give people an honest answer about whether what happened to them met the benchmark the profession sets for itself. That answer, whatever it is, is what most people are actually seeking.

This article contains general legal information only. It does not constitute legal advice, and reading it does not create a lawyer–client relationship. The law discussed applies to New South Wales, Australia. Each person’s circumstances differ. Time limits apply to legal claims in NSW, and these limits may affect your position. You should seek independent legal advice about your specific situation.